Ependymomas are malignant brain and spinal cord gliomas, primarily affecting children and young adults. They comprise 3-9% of all primary central nervous system (CNS) tumors (6-12% in children, and 30% in patients o3 years of age). Established prognostic variables include age, tumor location, and extent of surgical resection. Histological grading has been less consistent, showing significant associations with clinical behavior mainly in the larger series with long follow-up. The molecular pathogenesis of ependymomas has also remained elusive and alterations common to other gliomas, specifically those of the astrocytoma subtype are not common. [1] [2] [3] [4] [5] [6] [7] [8] In contrast, there is at least some genetic overlap with another primary CNS tumor, the meningioma. The most consistent genetic changes in ependymoma have been chromosome 22 deletions in 30-70% of tumors, [9] [10] [11] with inactivating mutations of the NF2 tumor suppressor gene or loss of expression of its protein product, merlin (or schwannomin), in 29-38% of spinal ependymomas. [12] [13] [14] [15] [16] Such mutations have been rare in the intracranial counterparts.
NF2 is one of the key growth regulatory members of the cell membrane/cytoskeleton-associated Protein 4.1 superfamily, characterized by homologous FERM domains and functional roles in membrane trafficking, cell-cell adhesion, cell motility, and signal transduction. 17, 18 In a pilot study of 27 ependymomas, we found evidence for involvement of a second family member, 4.1B on 18p11.3 (previously known as DAL-1 for 'differentially expressed in adenocarcinoma of the lung 1'). 16 In contrast to NF2, 4.1B alterations were seen almost exclusively in the intracranial tumors, suggesting the possibility of differential involvement of Protein 4.1 members according to tumor site. However, this trend did not reach statistical significance in our preliminary study. Also, since the majority of ependymomas had neither NF2 nor 4.1B losses, other critical genetic alterations likely exist.
There are several reasons to suspect two additional Protein 4.1 family members (the erythrocyteassociated 4.1R on 1p32-33 and the more ubiquitously expressed 4.1G on 6q23) might represent candidate ependymoma tumor suppressor genes. First, both of these cytogenetic loci are commonly implicated as sites of either deletion or rearrangement in ependymomas. [9] [10] [11] [19] [20] [21] Secondly, both of these family members are highly expressed in the brain. 22, 23 Lastly, we have demonstrated a growth regulatory role for several Protein 4.1 family members in meningiomas, [24] [25] [26] and preliminary studies have shown that the reintroduction of Protein 4.1R into 4.1R-negative meningioma cell lines results in growth suppression. 27 Based on these observations, we decided to study the Protein 4.1 family members in a larger set of ependymomas. Our data suggest that particular alterations in Protein 4.1 gene dosage and expression are associated with specific clinicopathologic subsets of ependymoma.
Materials and methods
An ependymoma tissue microarray was created using clinically and pathologically well characterized, archival specimens from Washington University School of Medicine. We retrieved and reviewed archival slides and blocks from 84 ependymomas (51 intracranial and 33 spinal) resected between 1967 and 2002, with application of current World Health Organization (WHO) classification and grading criteria. 1 Three representative regions were selected per case and 0.6-mm cores were extracted from the corresponding donor block, yielding a final tissue microarray block containing approximately 350 tissue cores (including cores from normal lung as controls). Sections of 5 mm thickness were cut and mounted onto poly-L-lysine-coated slides for fluorescence in situ hybridization (FISH) and immunohistochemistry. Immunohistochemical stains were originally performed on TMA sections, but unfortunately were not interpretable due to problems with high background. Therefore, immunohistochemistry was repeated on whole tissue sections in a subset of 52 cases.
Dual colored FISH was performed as previously reported. 8, 16, 26, 27 Sources of DNA probes are summarized in Table 1 . The tissue sections were deparaffinized and subjected to target retrieval by steam cooking in citrate buffer (20 min), cooling (20 min) and washing (5 min) followed by pepsin digestion (4 mg/ml at 371C for 30 min). The slides were washed in 2 Â saline-sodium citrate (SSC) for 5 min and air-dried. The probes were diluted in DenHyb hybridization buffer (1:25) (Insitus Laboratories, Albuquerque, NM, USA) and paired [4 
. A volume of 10 ml of the hybridization mix was applied to each slide, and the probe and the target DNA were simultaneously denatured at 901C for 13 min. Following overnight hybridization at 371C in a humidified chamber, the slides were washed at room temperature in 50% formamide/1 Â SSC for 5 min followed by a wash in 2 Â SSC for 5 min. The slides were airdried and counterstained with DAPI (0.5 ml/ml; Insitus Laboratories). Sections were viewed under an Olympus BX60 fluorescent microscope with appropriate filters (Olympus, Melville, NY, USA) and those showing 490% nuclei with signals were evaluated, with 100 intact nonoverlapping nuclei scored for the number of fluorescent signals. Hybridizations were digitally photographed using a high-resolution black and white COHU chargecoupled device (CCD) camera, with a Z-stack motor programmed to capture images at sequential DAPI (1 level), fluorescein isothiocyanate (FITC) (10 levels), and rhodamine (10 levels) filter settings. Reconstruction into a single superimposed image with blue, green, and red pseudocolors was accomplished using a CytoVisionTM basic workstation (Applied Imaging, Santa Clara, CA, USA).
Immunohistochemistry was performed as previously published. 13, 16, [24] [25] [26] [27] Slides were deparaffinized and treated with 3% hydrogen peroxide to remove endogenous peroxidase activity. Antigen Associations between frequencies of genetic alterations, tumor location (intracranial vs spinal) and patient age (pediatric or adult) were evaluated based on the Fisher's exact test. Reported P-values of o0.05 were considered statistically significant.
Results
The study cohort consisted of 51 intracranial tumors; 41 posterior fossa ependymomas from patients ranging in age from 7 months to 72 (median 7) years and 10 supratentorial ependymomas from patients ranging in age from 4 to 35 (median 13) years. There were 33 spinal ependymomas from patients ranging from 13 to 69 (median 41) years of age. Stratified by age, there were 40 pediatric (eight supratentorial, 28 posterior fossa, and four spinal) and 44 adult (two supratentorial, 13 posterior fossa and 29 spinal) tumors. The age range for the pediatric group was 7 months to 18 years (mean ¼ 6 6 years, median ¼ 4 years) and the adults ranged from 22 Figure 1 . The FISH and immunohistochemistry data in relation to patient age, tumor site, and histologic grade are summarized in Figures 2 and 3 . By FISH (Figures 2a  and 3a) , 80% of the intracranial tumors and 66% of the spinal tumors showed deletion of at least one of the Protein 4.1 family member genes. Although there were slightly more NF2 deletions in spinal versus intracranial tumors, these differences did not reach statistical significance. In contrast, 4.1B deletions were statistically significantly more common in pediatric than adult (62 vs 19%; Po0.001), intracranial than spinal (49 vs 25%; P ¼ 0.038), and grade III than either grade II alone (73 vs 45%; P ¼ 0.003) or grades I and II combined (73 vs 29%; Po0.001). 4.1R and 4.1G deletions were less common and did not differ significantly in subsets stratified according to patient age, tumor site, or histologic grade. Polysomies were seen in roughly 10% of all cases and did not have any statistically significant associations with specific clinicopathologic subsets.
By immunohistochemistry, losses of Protein 4.1R expression were common (Figures 2b and 3b) . These losses were statistically associated with young age (pediatric: 93% vs adult: 48%; Po0.001), intracranial location (intracranial: 88% vs spinal: 47%; P ¼ 0.003), and high-grade tumor (III: 95% vs II: 63%; P ¼ 0.022 or III: 95% vs I/II: 59%; P ¼ 0.007). Expression levels of merlin and Protein 4.1B did not differ significantly among these subsets.
In a selected series of ependymomas in which sufficient frozen tumor was available, Western blot analysis showed losses of Protein 4.1R in all nine ependymomas examined (Figure 4) . Protein 4.1B loss was seen in three of four intracranial tumors and one of five spinal cord tumor. Loss of merlin expression was found in two of five spinal cord tumors, with retained expression in all four intracranial cases.
Clinical follow-up was available for 43 of 51 intracranial tumors for a median of 29 months (range 4-242 months, mean ¼ 53 months) and for 29 of 33 spinal tumors for a median of 27 months (range 2-150 months, mean ¼ 44 months). There were 15 patients who had died of their disease (14 intracranial, one spinal), 14 alive with recurrences or residual disease (nine intracranial, five spinal), and 43 with no evidence of disease (19 intracranial, 24 spinal). Only one genetic alteration, 4.1G deletion, was statistically associated with clinical outcome, in that it was encountered in 41% of patients with death, recurrence, or residual disease vs 12% of patients with no evidence of disease (P ¼ 0.009). 
Discussion
Although our understanding of ependymoma genetics remains limited, a growing body of literature supports differing molecular mechanisms of tumor pathogenesis for adult, intracranial and spinal ependymomas. 28 Our findings further support this notion, demonstrating statistically significant associations for specific Protein 4.1 alterations within distinct clinicopathologic subsets of ependymoma. Specifically, we found that 4.1B (18p11.3) deletions and losses of Protein 4.1R expression were each more common in the pediatric, intracranial, and/or anaplastic (WHO grade III) ependymoma subsets. Also, 4.1G (6q23) deletions were associated with the more aggressive clinical disease, encountered mostly in patients that either died of their tumor or had residual/recurrent tumor at last follow-up. Losses of chromosome 6q have often been implicated in studies of ependymomas in the past and as in our cases, have been found to be particularly common in pediatric ependymomas. 19 However, specific associations between this alteration and distinct clinicopathologic subsets had not been thoroughly explored previously. The precise pathogenic roles for 4.1G and other Protein 4.1 family members in ependymoma and potential mechanisms of inactivation remain to be elucidated. Given the fact that deletions at the DNA level often did not correlate well with losses of the protein products in our series, it is likely that other candidate genes at these cytogenetic sites are more relevant than the ones we chose to study. Nevertheless, the potential for an independent genetic marker of prognosis at 6q23 could be of great clinical benefit, given the relatively poor predictability of ependymoma biology using histology alone. This association should therefore be explored further and confirmed in an independent patient cohort. Similarly, losses of Protein 4.1R protein expression were considerably more common than 4.1R gene deletions detected by FISH. This suggests the possibility of other mechanisms of inactivation, such as mitotic recombination or hypermethylation of CpG islands. Additional studies will be needed to clarify this issue.
In terms of associations with tumor location, we found that similar to our prior study, 4.1B deletions were more common in intracranial than spinal ependymomas. 16 Whereas this difference did not reach statistical significance previously, it did in the current series likely due to the larger numbers of tumors utilized. This trend remained true on Western blot, though those numbers were small. Surprisingly, we did not find a predilection for NF2 deletions or merlin losses in the spinal tumors, as has been previously reported. [12] [13] [14] [15] [16] At the DNA level, this could be explained by the fact that intracranial ependymomas also harbor chromosome 22 deletions, particularly in pediatric cases. It is suspected that another tumor suppressor on chromosome 22q besides NF2 is involved in such cases, though a specific candidate has yet to be identified. At the protein level, the lack of association with spinal localization is more puzzling. The interpretation of merlin immunohistochemistry in paraffin-embedded tissue can be challenging and it is possible that this factor contributed to this apparent discrepancy in our study. In comparison, Western blot analysis revealed two of five (40%) spinal cases with merlin loss, with all four of the intracranial counterparts retaining protein expression. Therefore, our Western blot data are consistent with the findings previously reported in the literature, though the numbers examined are too small for statistical analysis.
We conclude that DNA and protein alterations of Protein 4.1 family members are common in ependymomas. Specific alterations are statistically associated with distinct clinicopathologic features, such as patient age, tumor location, histologic grade, and/or biologic behavior. Additional studies are warranted to elucidate the pathogenic roles of these candidate genes, mechanisms of inactivation, prognostic utility of individual biomarkers, and the potential involvement of other candidate genes in close cytogenetic proximity.
